Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 ...

The discovery and development of drugs in pharmacological research – including the risk assessment of active substances in the early phase of drug development – still largely relies on animal ...

Part of the issue lies in early-phase drug design and discovery which requires testing of multiple molecules before anything can be taken forward to later developmental stages. Pharmaceutical ...

Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence (AI). Traditionally, drug development has been a lengthy, costly, and ...

Five years since it launched, advances powered by the National Drug Discovery Centre are helping transform medical research in Australia and fast-tracking development of new home-grown treatments.

with two additional pipelines progressing toward clinical stages. By combining the power of novel organoid disease models and AI, Signet is reshaping drug discovery and paving the way for more ...

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.